KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.

MLA

Camaj, Peter, et al. “KRAS Exon 2 Mutations Influence Activity of Regorafenib in an SW48-Based Disease Model of Colorectal Cancer.” Future Oncology (London, England), vol. 11, no. 13, 2015, pp. 1919–29. EBSCOhost, https://doi.org/10.2217/fon.15.97.

APA

Camaj, P., Primo, S., Wang, Y., Heinemann, V., Zhao, Y., Laubender, R. P., Stintzing, S., Giessen-Jung, C., Jung, A., Gamba, S., Bruns, C. J., & Modest, D. P. (2015). KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. Future Oncology (London, England), 11(13), 1919–1929. https://doi.org/10.2217/fon.15.97

Chicago

Camaj, Peter, Stefano Primo, Yan Wang, Volker Heinemann, Yue Zhao, Ruediger Paul Laubender, Sebastian Stintzing, et al. 2015. “KRAS Exon 2 Mutations Influence Activity of Regorafenib in an SW48-Based Disease Model of Colorectal Cancer.” Future Oncology (London, England) 11 (13): 1919–29. doi:10.2217/fon.15.97.